Slifka M K, Ahmed R
Emory Vaccine Center, Emory University School of Medicine, Atlanta, Georgia 30307, USA.
Ann N Y Acad Sci. 1996 Oct 25;797:166-76. doi: 10.1111/j.1749-6632.1996.tb52958.x.
Acute viral infection of humans induces virus-specific serum antibody production that often persists for decades. To better understand the nature of this long-term antiviral antibody response, we studied antiviral antibody production of mice acutely infected with lymphocytic choriomeningitis virus (LCMV). Although this viral infection is resolved within 2 weeks, virus-specific serum antibody levels were maintained for > 300 days postinfection. The anatomic site of long-term antibody production was identified using an ELISPOT assay to quantitate LCMV-specific antibody-secreting cells (ASC). The initial antiviral ASC response in the spleen peaked at 8 days postinfection and then declined sharply, with less than 10% of the day 8 ASC population remaining after 60 days. Although no LCMV specific ASC were detected in the bone marrow at day 8, virus-specific ASC began accumulating in the bone marrow by 15 days postinfection. By day 60, approximately 10-fold more antiviral ASC were present in the bone marrow than in the spleen, and the bone marrow remained the major site of antibody production for > 10 months postinfection. To further characterize the LCMV-specific antibody response, the relative percentage of each IgG subclass (IgG1, IgG2a, IgG2b, and IgG3) was determined. IgG2a was the predominant IgG subclass produced during LCMV infection, and the IgG subclass profile of virus-specific ASC in the spleen and bone marrow matched the IgG subclass profile of virus-specific IgG in the serum. Following a secondary infection with LCMV, splenic ASC numbers increased rapidly with a peak at 5 days after secondary infection. This was followed by a sharp decline in ASC numbers by day 15. In contrast, virus-specific ASC numbers in bone marrow remained essentially unchanged during the acute phase of the secondary infection but increased approximately twofold at day 15, corresponding to a twofold increase in virus-specific serum antibody levels. These results indicate that following a primary viral infection or upon reexposure to a virus, the initial antibody response occurs in the spleen, but long-term antiviral antibody production is maintained in the bone marrow.
人类急性病毒感染会诱导产生病毒特异性血清抗体,这种抗体通常会持续数十年。为了更好地理解这种长期抗病毒抗体反应的本质,我们研究了急性感染淋巴细胞性脉络丛脑膜炎病毒(LCMV)的小鼠的抗病毒抗体产生情况。尽管这种病毒感染在2周内即可消退,但感染后300多天病毒特异性血清抗体水平仍维持在较高水平。使用ELISPOT分析来定量LCMV特异性抗体分泌细胞(ASC),从而确定长期抗体产生的解剖部位。脾脏中最初的抗病毒ASC反应在感染后第8天达到峰值,然后急剧下降,60天后第8天的ASC群体中剩余不到10%。虽然在感染后第8天骨髓中未检测到LCMV特异性ASC,但感染后15天病毒特异性ASC开始在骨髓中积累。到第60天,骨髓中的抗病毒ASC数量比脾脏中多约10倍,并且在感染后10多个月内骨髓一直是抗体产生的主要部位。为了进一步表征LCMV特异性抗体反应,我们确定了每个IgG亚类(IgG1、IgG2a、IgG2b和IgG3)的相对百分比。IgG2a是LCMV感染期间产生的主要IgG亚类,脾脏和骨髓中病毒特异性ASC的IgG亚类谱与血清中病毒特异性IgG的IgG亚类谱相匹配。再次感染LCMV后,脾脏ASC数量迅速增加,在二次感染后第5天达到峰值。随后到第15天ASC数量急剧下降。相比之下,二次感染急性期骨髓中病毒特异性ASC数量基本保持不变,但在第15天增加了约两倍,这与病毒特异性血清抗体水平增加两倍相对应。这些结果表明,在初次病毒感染后或再次接触病毒时,最初的抗体反应发生在脾脏中,但长期抗病毒抗体产生则在骨髓中维持。